Arovella Therapeutics (ASX:ALA) has entered into an exclusive option to license multiple patent families from Baylor College of Medicine to broaden the utility and enhance the performance of its iNKT cell platform.
Arovella options advances Baylor College of technology to enhance iNKT cell platform
May 5, 2025 Australian Biotech
Latest Video
New Stories
-
Positive trial result for Immutep’s 'efti' in combination with MSD's anti-PD-1 therapy
May 5, 2025 - - Australian Biotech -
Arovella options advances Baylor College of technology to enhance iNKT cell platform
May 5, 2025 - - Australian Biotech -
FDA grants fast track designation for Alterity's ATH434 to treat multiple aystem atrophy
May 5, 2025 - - Australian Biotech -
New immune therapy treatment option for women diagnosed with advanced endometrial cancer
May 4, 2025 - - Latest News -
Stakeholders should hope for continuity in the health portfolio
May 4, 2025 - - Latest News -
UCB welcomes the PBS listing of dual-acting anti-seizure medication
May 4, 2025 - - Latest News -
Pharma, pharmacy and biotech congratulate Government for re-election
May 4, 2025 - - Latest News